HALO

Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing solutions to improve patient experiences and outcomes for emerging and established therapies. The Company's commercially-validated solution, ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, is used to facilitate the subcutaneous delivery of injected drugs and fluids, with a focus on improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. The Company licenses its technology to biopharmaceutical companies to collaboratively develop products that combine ENHANZE with its partners’ proprietary compounds. It also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies. The Company has two commercial proprietary products, Hylenex and XYOSTED. It also has a proprietary ultra-high concentration microparticle formulation technology for biologics, branded Hypercon.

Wall Street analysts forecast HALO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HALO is 77.63 USD with a low forecast of 56.00 USD and a high forecast of 92.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Halozyme Therapeutics Inc revenue for the last quarter amounts to 354.26M USD, increased 22.12 % YoY.

Halozyme Therapeutics Inc. EPS for the last quarter amounts to 1.43 USD, increased 36.19 % YoY.

Halozyme Therapeutics Inc (HALO) has 350 emplpoyees as of December 15 2025.

Today HALO has the market capitalization of 7.32B USD.